Xtandi (Enzalutamide) Patent Expiration, LOE Window & CMS Spending
Xtandi (Enzalutamide) by Astellas Pharma: FDA Orange Book core substance LOE 2027-08-13 (last listed 2037-02-23), 1 AB generics, $3.55B 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Astellas Pharma |
| FDA Application & Pathway | N203415 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2027-08-13 |
| Last Listed Patent or Exclusivity Date | 2037-02-23 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $3.55B |
| 2024 Medicare Part D Spend | $3.40B |
| 2024 Medicaid Spend | $151.2M |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 16.8% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.